Evaluation of the antineoplastic activities of the riminophenazine agents clofazimine and b669 in tumor-bearing rats and mice.

The riminophenazine agents clofazimine and its analogue B669 displayed anti-tumor activity at 30 mg/kg/day in benzo[a]pyrene (BP) induced sarcomas of mice as well as dimethylbenz-anthracene (DMBA)-induced rat mammary tumors. No hematological toxicity of these drugs at doses up to 60 mg/kg/day for one month was observed. This is the first study to document in vivo anti-neoplastic activities of clofazimine and B669.